{'52WeekChange': 1.7432432,
 'SandP52WeekChange': None,
 'address1': '21 Erie Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 19.27,
 'askSize': 800,
 'averageDailyVolume10Day': 238175,
 'averageVolume': 354925,
 'averageVolume10days': 238175,
 'beta': 2.180505,
 'beta3Year': None,
 'bid': 19,
 'bidSize': 800,
 'bookValue': 1.702,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 20.4,
 'dayLow': 19.22,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -13.398,
 'enterpriseToRevenue': 126.089,
 'enterpriseValue': 502884480,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 23.586,
 'fiftyTwoWeekHigh': 31.69,
 'fiftyTwoWeekLow': 6.95,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 19460625,
 'forwardEps': -1.74,
 'forwardPE': -11.057471,
 'fromCurrency': None,
 'fullTimeEmployees': 45,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.15235,
 'heldPercentInstitutions': 0.43418998,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/cuebiopharma.com',
 'longBusinessSummary': 'Cue Biopharma, Inc., a biopharmaceutical company, '
                        'develops biologic drugs for the selective modulation '
                        'of the human immune system to treat a range of '
                        'cancers, chronic infectious diseases, and autoimmune '
                        'disorders. Its lead drug candidate CUE-101, a protein '
                        'biologic that is in Phase I clinical trials designed '
                        'to target and activate antigen-specific T cells for '
                        'human papilloma virus driven cancers. The company '
                        'offers CUE-102, an onco-fetal viral antigen for '
                        'cancers, including solid tumors and hematologic '
                        'malignancies; CUE-103, an antigen; CUE-200 framework '
                        'that includes CD80 and/or 4-1BBL to reactivate '
                        'exhausted T cells and design to enhance '
                        'antigen-specific T cell for the treatment of chronic '
                        'infectious diseases; and CUE-300 framework to target '
                        'various autoimmune diseases. It has collaboration '
                        'agreements with Merck Sharp & Dohme Corp. for the '
                        'research and development of its proprietary biologics '
                        'that target various autoimmune disease indications; '
                        'LG Chem Life Sciences for Immuno-selective targeting '
                        'and alteration of T cells (STAT) in the field of '
                        'oncology; and Albert Einstein College of Medicine to '
                        'develop Immuno-STAT biologics for chronic infectious '
                        'diseases, as well as a strategic research '
                        'collaboration with Dr. Michael Dustin and Oxford '
                        'University. The company was formerly known as Imagen '
                        'Biopharma, Inc. and changed its name to Cue '
                        'Biopharma, Inc. in October 2016. Cue Biopharma, Inc. '
                        'was incorporated in 2014 and is headquartered in '
                        'Cambridge, Massachusetts.',
 'longName': 'Cue Biopharma, Inc.',
 'market': 'us_market',
 'marketCap': 547374144,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_417883814',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -38249956,
 'nextFiscalYearEnd': 1640908800,
 'open': 20.1,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617 949 2680',
 'previousClose': 20.3,
 'priceHint': 2,
 'priceToBook': 11.304348,
 'priceToSalesTrailing12Months': 137.24391,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 20.4,
 'regularMarketDayLow': 19.22,
 'regularMarketOpen': 20.1,
 'regularMarketPreviousClose': 20.3,
 'regularMarketPrice': 20.1,
 'regularMarketVolume': 391467,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 28449800,
 'sharesPercentSharesOut': 0.061100002,
 'sharesShort': 1738344,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 622029,
 'shortName': 'Cue Biopharma, Inc.',
 'shortPercentOfFloat': 0.063200004,
 'shortRatio': 4.02,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'CUE',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.627,
 'twoHundredDayAverage': 20.511906,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '13b1e122-c7bb-3180-b359-74c89c132432',
 'volume': 391467,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.cuebiopharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}